

# Svenska Handelsbanken

## Press Release

Stockholm 5 June 2001

### Handelsbanken Investment Banking recruits top-calibre analyst

Handelsbanken Investment Banking has recruited Annika Espander to its research department. She will have overall responsibility for pharmaceuticals on a global level as well as biotechnology and medical technology.

"I am delighted to have Annika on board. If you want to be a first-class market player, it is vital to continually recruit first-class staff," says Michael Matzen, Head of Equities at Handelsbanken Investment Banking

Annika Espander was most recently employed at Enskilda Securities. She has a background as a molecular biologist and also has an MBA.

Handelsbanken aims to further enhance its position in investment banking. Health-care is one of the highest priority areas and the Bank's ambition is to achieve a leading position in both equities and corporate finance.

"We aim to stay at the top of the field in the Nordic countries and in selected international markets. In order to retain – and enhance – this position, we need recruitments of a high calibre like this," says Michael Matzen.

Handelsbanken Investment Banking has 460 employees in the Nordic countries, the UK, France and the USA and reported profits of SEK 118 million for the first quarter of 2001.

*For further information please contact:*

*Michael Matzen, Head of Equities, Handelsbanken Investment Banking,  
tel: +46 8-701 2389*

*Lars Höglund, Head of Research, Handelsbanken Investment Banking  
tel: +46 8-701 5170*